30 results
6-K
CNTB
Connect Biopharma Holdings Ltd
1 Jun 23
Current report (foreign)
4:24pm
, Connect Biopharma Holdings Limited (the “Company”) announced positive long-term data through Week 48 of CN002 Phase 2 trial for icanbelimod (formerly known … : Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
16 Apr 24
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
4:20pm
. Rademikibart was generally well tolerated with no unexpected safety signals.
oAnnounced positive long-term data from the China pivotal trial in patients … positive long-term data from the maintenance period through Week 48 of CN002 phase 2 icanbelimod trial in patients with moderate-to-severe ulcerative
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
and Chief Executive Officer of Connect Biopharma. “We also reported positive long-term data from the Phase 2 maintenance period in ulcerative colitis with our … expected by end of 2023.”
First Half 2023 and Recent Highlights
Reported in June 2023 positive long-term data from the maintenance period through Week 48
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
1 Jun 23
Current report (foreign)
4:24pm
Exhibit 99.1
Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through
Week 48 of CN002 Phase 2 Icanbelimod Trial … Maintenance Period
Icanbelimod was well-tolerated and long-term safety data through Week 48 remained consistent with safety findings observed
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
11 Apr 23
Connect Biopharma Reports Full Year 2022 Financial Results
5:00pm
partnerships to progress CBP-307 into future trials in UC and Crohn’s disease.
2022 Financial Results
Cash, cash equivalents, and short-term and long-term investments … )
As of December 31,
RMB’000
USD'000(1)
Cash, cash equivalents, short-term and long-term investments
Total assets
Total liabilities
Accumulated losses
Total
6-K
EX-99.1
21bqi1n 3c
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
6-K
cdq 5dxq2t6
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
6-K
EX-99.1
bqsyvu0d
5 Jun 23
Current report (foreign)
4:28pm
6-K
EX-99.1
hp1qf2rd
8 Sep 21
Connect Biopharma Announces First Subject Dosed in Phase 2 Trial Evaluating
8:31am
6-K
EX-99.2
jtcmzytclhh1hr9vp7s6
21 Nov 23
Exclusive License and Collaboration Agreement
6:13am
6-K
EX-99.2
4zm62trskvw
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
20-F
EX-4.10
n0rs9r eajai8wd
31 Mar 22
Annual report (foreign)
4:33pm
6-K
qfkv7z hz7kd
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
F-1
EX-10.15
xhdayddenlti2zbd
26 Feb 21
Registration statement (foreign)
4:56pm
6-K
EX-99.1
j8gr4zdxn2g
31 Aug 21
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:16pm
F-1
EX-10.12
4vuvx7fqptlgsbw
26 Feb 21
Registration statement (foreign)
4:56pm
DRS
spedo8 yzufc8fd2yt
17 Dec 20
Draft registration statement
12:00am
F-3
EX-1.2
msjr9 11a76rq9
15 Apr 22
Shelf registration (foreign)
5:27pm